Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Curr Hematol Malig Rep. 2007 Jul;2(3):169-75. doi: 10.1007/s11899-007-0023-1.
The current treatment programs for adult patients with acute lymphoblastic leukemia are modeled on pediatric regimens. The result has been complete remission rates comparable to those seen in children, but a significant proportion of adult patients relapse. Salvage therapy for patients with acute lymphoblastic leukemia continues to have limited success. Advances in molecular biology have discovered new targets for therapeutic intervention, and the introduction of some targeted agents, such as the new tyrosine kinase inhibitors and monoclonal antibodies, has led to improvements in response and survival in some subsets. The development of techniques for identification and monitoring of minimal residual leukemia has provided possible ways to predict relapse and consider early intervention. It is likely that we will further refine therapeutic approaches and improve patient outcome through the translation of biologic and molecular discoveries into effective and risk-adapted strategies.
目前针对成人急性淋巴细胞白血病的治疗方案是基于儿科方案制定的。其结果是完全缓解率与儿童相当，但仍有相当一部分成人患者复发。对于急性淋巴细胞白血病患者的挽救性治疗仍然收效甚微。分子生物学的进步发现了治疗干预的新靶点，一些靶向药物的引入，如新型酪氨酸激酶抑制剂和单克隆抗体，已经导致某些亚组的反应和生存得到改善。识别和监测微小残留白血病的技术的发展为预测复发和考虑早期干预提供了可能的途径。通过将生物学和分子发现转化为有效和适应风险的策略，我们很可能进一步完善治疗方法并改善患者的预后。
